Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 28 clinical trials
Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Lung cancer remains the most lethal malignancy in both sexes around the world. It is estimated that lung cancer caused 234,030 deaths in the United States in 2016, accounting for 28% of all cancer-related deaths. In 2012 alone, a total of 6,697 deaths from lung cancer were registered in Mexico; …

  • 0 views
  • 18 Feb, 2021
  • 1 location
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Retrospective Study (SELECT-1)

This is a nationwide, multicenter and retrospective cohort study. The purpose of this study is to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cell lung cancer.

lung carcinoma
EGFR
  • 0 views
  • 15 Jul, 2022
  • 17 locations
A Retrospective Pharmacogenomics Research of EGFR-TKIs Gefitinib and Erlotinib in NSCLC Patients Treatment

detection and gefitinib and erlotinib administration based on EGFR-TKIs sensitive mutations.From clinical points of view ,individual differences often occur between different patients, leading diverse

lung carcinoma
crizotinib
erlotinib
EGFR
gefitinib
  • 4 views
  • 26 Jan, 2021
  • 1 location
A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care

like erlotinib and vemurafenib. However, tumor genotyping can be slow and cumbersome, and is limited by availability of tumor biopsy tissue for testing. The aim of this study is to prospectively

advanced lung cancer
BRAF
immunologic adjuvant
NRAS
lung cancer
  • 10 views
  • 12 Mar, 2022
  • 1 location
Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

This study aims to explore the efficacy and safety of Erlotinib/Gefitinib combined with bevacizumab in the real world for advanced non-squamous cell lung cancer with EGFR mutation, explore new

bevacizumab
lung carcinoma
erlotinib
EGFR
gefitinib
  • 6 views
  • 14 Mar, 2022
  • 1 location
Osimertinib for Advanced EGFR-positive NSCLC Patients

EGFR-TKIs gefitinib and erlotinib bind competitively to the ATP-binding site of EGFR TK domain. This binding in second-generation TKI afatinib is irreversible. These drugs have improved better outcome

osimertinib
lung carcinoma
erlotinib
afatinib
cancer chemotherapy
  • 0 views
  • 16 Sep, 2021
  • 1 location
Study on Bisphosphonates Targeting Triple-negative Breast Cancer

can be chimeric with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, which can synergistically inhibit the in vitro tumor formation of cancer (such as non-small-cell lung

metastasis
HER2
estrogen receptor
erbb2
progesterone
  • 2 views
  • 30 Jul, 2021
  • 3 locations
Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung Cancer (RESISTYR)

compared to TKIs of previous generations (erlotinib, gefitinib). However, the response to osimertinib is heterogeneous and some patients are poor responder. In addition, even when an initial response to

  • 0 views
  • 09 May, 2022
  • 1 location